Mogroside V

产品说明书

Print
Chemical Structure| 88901-36-4 同义名 : 罗汉果苷 V
CAS号 : 88901-36-4
货号 : A889797
分子式 : C60H102O29
纯度 : 95%
分子量 : 1287.43
MDL号 : MFCD00238649
存储条件：

Pure form Sealed in dry, room temperature

In solvent -20°C:3-6个月-80°C:12个月
溶解度 :

DMSO: 105 mg/mL(81.56 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

H2O: 50 mg/mL(38.84 mM)，配合低频超声助溶
动物实验配方：
生物活性
描述 Mogroside V (MV) is a triterpenoid glycoside and a nonsugar sweetener. MV significantly ameliorated hepatic steatosis in high-fat diet- (HFD-) fed mice. Furthermore, the increased protein expression of PPAR-γ, SREBP-1, and FASN and mRNA expression of pparg, srebp1, scd1, and fasn in the liver in HFD-fed mice, which contribute to de novo lipogenesis, were dose-dependently reversed by MV treatment[3]. Mogroside V can effectively maintain normal oocyte morphology and early embryo development competence after prolonged culture for 24 h. Moreover, mogroside V can markedly reduce reactive oxygen species (ROS) levels, alleviate spindle formation and chromosome alignment abnormalities, improve mitochondrial contents, adenosine triphosphate (ATP) levels and the membrane potential (ΔΨm), and reduce early apoptosis in aged oocytes[4]. MV can protect oocytes from LPS-induced meiotic defects in part by reducing oxidative stress and maintaining m6A levels[5]. MV might alleviate oocyte meiotic defects and quality deterioration in BaP (benzo(a)pyrene)-exposed mice[6]. Mog (Mogroside V) might play a protective role against LPS-induced neurotoxicity by inhibiting the TLR4(toll-like receptor 4)-MyD88 (myeloid differentiation factor 88) and activation of AMPK/AKT-Nrf2 signaling pathway[7].
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

0.78mL

0.16mL

0.08mL

3.88mL

0.78mL

0.39mL

7.77mL

1.55mL

0.78mL
参考文献

[1]Shi D, Zheng M, et al. Protective effects and mechanisms of mogroside V on LPS-induced acute lung injury in mice. Pharm Biol. 2014 Jun;52(6):729-34.

[2]Deng F, Liang X, et al. Analysis of Mogroside V in Siraitia grosvenorii with micelle-mediated cloud-point extraction. Phytochem Anal. 2013 Jul-Aug;24(4):381-5.

[3]Li L, Zheng W, Wang C, Qi J, Li H. Mogroside V Protects against Hepatic Steatosis in Mice on a High-Fat Diet and LO2 Cells Treated with Free Fatty Acids via AMPK Activation. Evid Based Complement Alternat Med. 2020 Apr 30;2020:7826874

[4]Nie J, Sui L, Zhang H, Zhang H, Yan K, Yang X, Lu S, Lu K, Liang X. Mogroside V protects porcine oocytes from in vitro ageing by reducing oxidative stress through SIRT1 upregulation. Aging (Albany NY). 2019 Oct 6;11(19):8362-8373

[5]Yan K, Cui K, Nie J, Zhang H, Sui L, Zhang H, Yang X, Xu CL, Liang X. Mogroside V Protects Porcine Oocytes From Lipopolysaccharide-Induced Meiotic Defects. Front Cell Dev Biol. 2021 Mar 2;9:639691

[6]Sui L, Yan K, Zhang H, Nie J, Yang X, Xu CL, Liang X. Mogroside V Alleviates Oocyte Meiotic Defects and Quality Deterioration in Benzo(a)pyrene-Exposed Mice. Front Pharmacol. 2021 Aug 26;12:722779

[7]Liu Y, Zhang B, Liu J, Qiao C, Xue N, Lv H, Li S. Mogroside V Alleviates Lipopolysaccharide-Induced Neuroinflammation via Inhibition of TLR4-MyD88 and Activation of AKT/AMPK-Nrf2 Signaling Pathway. Evid Based Complement Alternat Med. 2021 Apr 30;2021:5521519